Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia

Phase 1

Completed

Conditions: Iron Deficiency Anemia

First Posted Date: 2006-11-14

Last Posted Date: 2010-03-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 15

Registration Number: NCT00399191

Locations: 🇺🇸
UT Southwestern, Dallas, Texas, United States

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: sunitinib malate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-11-10

Last Posted Date: 2014-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00398112

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Phase 2

Completed

Conditions: Recurrent Pancreatic Cancer
Acinar Cell Adenocarcinoma of the Pancreas
Duct Cell Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer

Interventions: Drug: sunitinib malate

First Posted Date: 2006-11-10

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT00397787

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

Phase 2

Completed

Conditions: Stage IIIC Skin Melanoma
Recurrent Melanoma
Stage IIIB Skin Melanoma
Stage IV Skin Melanoma

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Temsirolimus
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2006-11-10

Last Posted Date: 2017-06-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00397982

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: lenalidomide
Drug: temsirolimus
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-11-10

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00398515

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

Phase 2

Terminated

Conditions: Adenocarcinoma of the Rectum
Stage IV Rectal Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Adenocarcinoma of the Colon
Recurrent Colon Cancer

Interventions: Drug: saracatinib
Other: laboratory biomarker analysis

First Posted Date: 2006-11-10

Last Posted Date: 2019-08-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT00397878

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Colon
Gastrointestinal Stromal Tumor
Metastatic Gastrointestinal Carcinoid Tumor
Recurrent Colon Cancer
Recurrent Esophageal Cancer
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Recurrent Adult Primary Liver Cancer
Recurrent Anal Cancer
Recurrent Basal Cell Carcinoma of the Lip
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity

Interventions: Drug: cetuximab
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2006-11-09

Last Posted Date: 2015-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT00397384

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Procedure: low-LET photon therapy

First Posted Date: 2006-11-01

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 408

Registration Number: NCT00394511

Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families

Terminated

Conditions: Nasopharyngeal Neoplasms

First Posted Date: 2006-10-27

Last Posted Date: 2020-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 952

Registration Number: NCT00393224

Locations: 🇨🇳
National Taiwan University, Taiwan, China

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Advanced Malignant Mesothelioma
Recurrent Malignant Mesothelioma

Interventions: Drug: sunitinib malate

First Posted Date: 2006-10-26

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00392444

Locations: 🇨🇦
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy